gemfibrozil d6

AH057 is a novel JAK inhibitor, effectively blocking the JAK/STAT pathways by directly inhibiting JAK1/2 kinase activities, and leading to compromised cell proliferation and invasion, increasing apoptosis, arrested cell cycles, and impairing tumor progression in vitro and in vivo

Gemfibrozil-D6 is intended for use as an internal standard for the quantification of gemfibrozil by GC- or LC-MS. Gemfibrozil (T1415) is a peroxisome proliferator-activated reporter α and PPARγ agonist. In vivo,gemfibrozil reduces serum total cholesterol,triglyceride,and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia. Gemfibrozil (T1415)reduces atherosclerotic plaque area,superoxide production,and expression of the genes encoding the NF-κB subunit p65 and chemokine (C-C)motif ligand 2 (CCL2)in ApoE-/- mice. Formulations containing gemfibrozil have been used in the treatment of high cholesterol.

Gemfibrozil-D6 (Standard) 是 Gemfibrozil-D6 的标准品，适用于定量分析、质量控制及生化实验等相关研究。Gemfibrozil-d6 用于通过气相色谱-质谱法或液相色谱-质谱法对Gemfibrozil进行定量分析时作为内标物。Gemfibrozil是一种过氧化物酶激活剂α和过氧化物酶激活受体γ激动剂。